Literature DB >> 28620840

Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study.

Claudia Fabiani1, Antonio Vitale2, Ida Orlando2, Jurgen Sota2, Marco Capozzoli3, Rossella Franceschini3, Mauro Galeazzi2, Gian Marco Tosi3, Bruno Frediani2, Luca Cantarini4.   

Abstract

Our aim was to prospectively investigate the impact of Behçet's disease (BD), disease activity, and clinical and demographic characteristics on different aspects of quality of life (QoL) measured by the short-form (SF)-36 QoL scale. We administered the SF-36 to 37 consecutive BD patients in different moments of disease activity, and to 23 healthy controls (HC). The eight subcategories of the SF-36 underwent statistical analysis for identifying differences and correlations. Compared to HC, BD patients showed significantly lower mean scores in all SF-36 QoL subscales except mental health and role-emotional. Females showed a poorer QoL compared to males. Disease activity evaluated by the BD Current Activity Form inversely correlated with physical functioning (ρ = -0.68, p < 0.0001), bodily pain (ρ = -0.68, p < 0.0001), role-physical (ρ = -0.64, p < 0.0001), vitality (ρ = -0.64, p < 0.0001), general health (ρ = -0.64, p < 0.0001), social functioning (ρ = -0.50, p = 0.0002), mental health (ρ = -0.48, p = 0.0004), and role-emotional (ρ = -0.40, p = 0.003). Mucosal, central nervous system (CNS), musculoskeletal and ocular manifestations were the main factors that negatively affected QoL in BD. For ocular disease, physical functioning was significantly impaired in patients with panuveitis compared to other ocular manifestations (p = 0.0002). Best-corrected visual acuity was inversely correlated with social functioning (ρ = -0.53, p < 0.0001), role-physical (ρ = -0.48, p < 0.0001), bodily pain (ρ = -0.46, p = 0.02), and mental health (ρ = -0.43, p < 0.0001). Patients with BD have a poorer QoL compared to HC, particularly for women, while the decline of QoL is closely related to the overall disease activity of BD. Single organ involvements may affect independently specific SF-36 subscales, especially mucosal, CNS, musculoskeletal, and ocular manifestations.

Entities:  

Keywords:  BDCAF; Behçet’s disease (BD); Disease activity; Quality of life (QoL); Uveitis

Mesh:

Year:  2017        PMID: 28620840     DOI: 10.1007/s11739-017-1691-z

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  34 in total

1.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  Prevalence of fibromyalgia in Turkish geriatric population and its impact on quality of life.

Authors:  Yeşim Garip; Dilek Öztaş; Tuba Güler
Journal:  Agri       Date:  2016-10

4.  Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease.

Authors:  G Mumcu; S Niazi; J Stewart; E Hagi-Pavli; B Gokani; N Seoudi; T Ergun; S Yavuz; M Stanford; F Fortune; H Direskeneli
Journal:  J Oral Pathol Med       Date:  2009-03-02       Impact factor: 4.253

5.  A composite index for determining the impact of oral ulcer activity in Behcet's disease and recurrent aphthous stomatitis.

Authors:  G Mumcu; H Sur; N Inanc; U Karacayli; H Cimilli; N Sisman; T Ergun; H Direskeneli
Journal:  J Oral Pathol Med       Date:  2009-07-15       Impact factor: 4.253

6.  The Quality of Life in Patients With Behçet's Disease.

Authors:  Ozlem Canpolat; Sabire Yurtsever
Journal:  Asian Nurs Res (Korean Soc Nurs Sci)       Date:  2011-12-15       Impact factor: 2.085

7.  Quality of life and its relation with disease severity in Behçet's disease.

Authors:  I Ertam; G Kitapcioglu; K Aksu; G Keser; A Ozaksar; H Elbi; I Unal; S Alper
Journal:  Clin Exp Rheumatol       Date:  2009 Mar-Apr       Impact factor: 4.473

8.  Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.

Authors:  F S Neves; J C B Moraes; S C Kowalski; C Goldenstein-Schainberg; L V Lage; C R Gonçalves
Journal:  Clin Rheumatol       Date:  2006-12-20       Impact factor: 3.650

9.  Genital ulcer severity score and genital health quality of life in Behçet's disease.

Authors:  Amal Senusi; Noha Seoudi; Lesley Ann Bergmeier; Farida Fortune
Journal:  Orphanet J Rare Dis       Date:  2015-09-22       Impact factor: 4.123

10.  Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

Authors:  Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Stefano Gentileschi; Elena Silvestri; Claudia Fabiani; Maria Letizia Urban; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-09-27       Impact factor: 3.650

View more
  15 in total

1.  Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics.

Authors:  Jurgen Sota; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Ida Orlando; Gian Marco Tosi; Bruno Frediani; Antonio Vitale; Silvana Guerriero; Florenzo Iannone; Lorenzo Vannozzi; Claudia Fabiani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2020-02-01       Impact factor: 3.397

2.  Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.

Authors:  Claudia Fabiani; Antonio Vitale; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Jurgen Sota; Lorenzo Vannozzi; Gerardo di Scala; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Marco Capozzoli; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2018-04-18       Impact factor: 2.980

3.  Identification of physical and psychosocial problems based on symptoms in patients with Behçet's disease.

Authors:  Hideyo Tsutsui; Hirotoshi Kikuchi; Hiroko Oguchi; Kyoko Nomura; Takayoshi Ohkubo
Journal:  Rheumatol Int       Date:  2019-12-04       Impact factor: 2.631

Review 4.  Phenotypes in Behçet's syndrome.

Authors:  Emire Seyahi
Journal:  Intern Emerg Med       Date:  2019-02-11       Impact factor: 3.397

5.  Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.

Authors:  Gülen Hatemi; Alfred Mahr; Mitsuhiro Takeno; Doyoung Kim; Melike Melikoğlu; Sue Cheng; Shannon McCue; Maria Paris; Mindy Chen; Yusuf Yazici
Journal:  RMD Open       Date:  2022-07

6.  Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments.

Authors:  Giacomo Emmi; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2019-07-17       Impact factor: 3.397

7.  Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience.

Authors:  Jurgen Sota; Luca Cantarini; Antonio Vitale; Arianna Sgheri; Stefano Gentileschi; Valeria Caggiano; Viviana Gelardi; Bruno Frediani; Gian Marco Tosi; Claudia Fabiani
Journal:  Mediators Inflamm       Date:  2020-05-15       Impact factor: 4.711

Review 8.  Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.

Authors:  Joanna C Robson; David Jayne; Peter A Merkel; Jill Dawson
Journal:  Patient Relat Outcome Meas       Date:  2019-02-08

9.  Impact of disease activity on health related quality of life in patients with Behçet's disease: A cross-sectional study.

Authors:  Faiq I Gorial; Mais Ajeel Jabbar
Journal:  Ann Med Surg (Lond)       Date:  2020-04-13

10.  Does illness perception associate with disease symptoms in Behçet's disease?

Authors:  Gonca Mumcu; Fedayi Yağar; Fatma Alibaz-Öner; Nevsun İnanç; Haner Direskeneli; Tulin Ergun
Journal:  Intern Emerg Med       Date:  2018-11-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.